Protagonist Therapeutics, a spin-out company from IMB, has begun clinical trials with a novel drug candidate being investigated as a potential 'oral targeted therapy' for inflammatory bowel diseases.
Protagonist Therapeutics, a spin-out company from The University of Queensland’s Institute for Molecular Bioscience (IMB), has raised $40 million to begin clinical trials of an oral drug for Inflammatory Bowel Disease.
UQ researchers are developing a new asthma treatment that targets the underlying cause of asthma, rather than just the symptoms. UQ Institute of Molecular Bioscience’s Associate Professor Mark Smythe said the research team was developing a new drug designed to offer patients a safer and more effective treatment.
IMB researchers have been awarded over $10 million from the National Health and Medical Research Council (NHMRC) to investigate pain relief, dengue fever vaccinations and asthma treatments.
